Ozempic (GLP-1) Lawsuit — Free Case Review
Which Medications — and Which Injuries — Qualify
Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Did this happen to you — or someone you love?
Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.
Partners
Matthew T. Marin & Stefanie A. Murphy
Super Lawyers® honorees · American Association for Justice members
Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.
The European Medicines Agency concluded on June 6, 2025 that NAION is a “very rare” side effect of semaglutide medicines and recommended adding it to EU product information. Australia’s TGA announced the same step in July 2026. As of September 23, 2026, verified against the FDA-posted prescribing information (Ozempic PI, NDA 209637 s038, revision 05/2026), the United States label for semaglutide does not list NAION and FDA has issued no NAION-specific safety communication or label change. This page records the dated sequence and nothing more.
This is a ledger, not an argument. Each entry below is a dated regulatory or scientific event with its source. What any of it means for any individual claim is a question for that person’s medical records and the courts, neither of which have resolved anything.
Free, confidential case review. Marin & Murphy is currently accepting Ozempic (GLP-1) NAION vision-loss and stomach-injury cases. No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Start a free case review or call (888) 348-2735 — answered 24/7.
See if you qualify
A few quick questions about which GLP-1 medication you took, your diagnosis and testing, and your treatment. This is the initial intake screening, not a full case review. Most people finish in about two minutes.
- 🔒 Confidential
- No obligation
- ⏱ ~2 minutes
Marin & Murphy Law Firm · Free & confidential · Stop messages anytime
The timeline
July 3, 2024 — JAMA Ophthalmology publishes the study that started it
Hathaway and colleagues at Massachusetts Eye and Ear published a retrospective cohort study of more than 17,000 patients over the six years following Ozempic’s release. The reported findings: patients with diabetes prescribed semaglutide were more than four times as likely to develop NAION, and patients who were overweight or obese and prescribed semaglutide were more than seven times as likely. This is a retrospective cohort study from a single specialty center, not a regulatory finding and not a causation determination. (doi:10.1001/jamaophthalmol.2024.2296)
June 6, 2025 — EMA’s PRAC concludes NAION is a very rare side effect
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee completed a review covering Ozempic, Rybelsus, and Wegovy. Its conclusion: NAION may affect up to 1 in 10,000 people taking semaglutide, which is the frequency category “very rare,” and EU product information should be updated to list it.
PRAC cited epidemiological evidence of roughly a two-fold increased NAION risk in adults with type 2 diabetes using semaglutide compared with non-users — approximately one additional case per 10,000 person-years of treatment. PRAC advised patients experiencing sudden vision changes to contact a physician immediately, and that semaglutide should be stopped if NAION is confirmed.
The World Health Organization circulated the conclusion to member states on June 27, 2025.
March 10, 2026 — British Journal of Ophthalmology FAERS analysis
A disproportionality analysis of more than 30 million FDA adverse event reports covering December 2017 through December 2024 identified a NAION reporting signal for semaglutide products, reported as nearly five times stronger for Wegovy than for Ozempic despite the identical active ingredient — a difference the authors attributed at least partly to differing patient populations and reporting behavior rather than to pharmacology. Disproportionality analyses measure reporting patterns. Reports submitted to FDA are not verified and do not establish causation.
July 2026 — Australia’s TGA announces NAION warnings
Australia’s Therapeutic Goods Administration announced that NAION warnings would be added to semaglutide product information, placing Australia alongside the EU and the UK’s MHRA among major regulators that have acted on this signal.
September 23, 2026 — the current US position
The most recent US Ozempic prescribing information is the FDA-posted revision dated May 2026 (Ozempic PI, NDA 209637 s038, revision 05/2026), and it does not include NAION-related warnings. No FDA Drug Safety Communication, label change, or recall specific to NAION had issued as of the July 2026 source dates checked. FDA is currently the outlier among these regulators on this specific signal.
What FDA has done on these medications, for completeness
| Date | Action | Relation to NAION |
|---|---|---|
| Sept 22, 2023 | FDA adds ileus (intestinal blockage) to the Ozempic label as a postmarketing-identified risk. Gastroparesis was not added as a named label term. | None — gastrointestinal |
| Sept 9, 2025 | FDA Warning Letter to Novo Nordisk (#716495) concerning promotional content that minimized serious risks and untimely submission of promotional material. | Does not mention NAION |
| Apr 30, 2026 | FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, following resolution of the shortages. | None — compounding |
| Sep 23, 2026 | No NAION entry on the US semaglutide label; no FDA safety communication on NAION. | Direct |
This entry can change on any day
The US label status is the fastest-decaying fact on this site. FDA could add a NAION warning, issue a safety communication, or decline to act, and any of those would change the last row of the table above without changing the rest of it. This page is dated September 23, 2026 for that reason, and it is reviewed against the label and FDA communications on a standing schedule. If you are reading it well after that date, check the date line at the top.
What this does and does not mean for a claim
A label difference between countries is a fact about labeling. It is not a court finding, and no court in the United States has found that these medications caused anyone’s NAION. What a US claim turns on is what the manufacturer knew, when it knew it, what the US label said at the time, and what that person’s own medical records show. As of October 2026 there are no settlements and no verdicts in any GLP-1 injury lawsuit, and no trial date has been set in either federal proceeding.
Free, confidential case review. Marin & Murphy is currently accepting Ozempic (GLP-1) NAION vision-loss cases. No fee unless there is a recovery. Marin & Murphy is licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; matters elsewhere may be referred to lawyers licensed in your state.
Start a free case review or call (888) 348-2735. We will tell you honestly if a claim would not move forward.
Common questions
Does the Ozempic label warn about NAION in the United States?
No. As of September 23, 2026, the US semaglutide label does not list NAION, and FDA has issued no NAION-specific safety communication or label change. The most recent prescribing information is the FDA-posted May 2026 revision (Ozempic PI, NDA 209637 s038, revision 05/2026).
What did the EMA actually conclude about NAION?
On June 6, 2025, EMA’s PRAC concluded that NAION is a very rare side effect of semaglutide medicines — affecting up to 1 in 10,000 people taking them — and recommended that EU product information be updated to list it. It cited roughly a two-fold increased risk in adults with type 2 diabetes using semaglutide, about one additional case per 10,000 person-years.
Which regulators have added NAION warnings?
The European Medicines Agency recommended an EU product-information update in June 2025; the UK’s MHRA has moved in the same direction; and Australia’s TGA announced in July 2026 that NAION warnings would be added to semaglutide product information. The WHO circulated the EMA conclusion to member states in June 2025.
Does a European warning mean the drug caused someone’s vision loss?
No. A regulator concluding that a very rare side effect should be listed is a labeling decision, not a finding about any individual. No court has found that these medications caused anyone’s injury.
Sources
- European Medicines Agency, “PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy),” June 6, 2025
- World Health Organization, member-state notice on semaglutide and NAION, June 27, 2025
- Hathaway JT, Zekavat SM, Shah MP, Hathaway DB, Rizzo J, et al., JAMA Ophthalmology, July 3, 2024, doi:10.1001/jamaophthalmol.2024.2296; Mass Eye and Ear press release
- British Journal of Ophthalmology FAERS disproportionality analysis, reported March 10, 2026 (secondary coverage)
- Therapeutic Goods Administration (Australia), reported July 2026 (secondary coverage)
- FDA Warning Letter to Novo Nordisk Inc., #716495, September 9, 2025
- FDA proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B bulks list, April 30, 2026
- Ozempic US prescribing information, NDA 209637 supplement s038, revision 05/2026 (FDA-posted document, accessdata.fda.gov)
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone’s injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Attorney Advertising.
This page is attorney advertising and is for informational purposes only; it is not legal or medical advice. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship.
Related vision-loss topics: “eye stroke” (NAION), sudden vision loss in one eye, risk to the other eye, and NAION vision-loss claims.
The data: FDA adverse-event data, FAERS reports by injury, the FAERS methodology, and the lawsuit tracker.
More on the Ozempic (GLP-1) litigation
- Ozempic lawsuit overview (hub)
- Ozempic & GLP-1 lawsuit tracker
- Settlement amounts: what’s actually known
- Verdicts & settlements ledger
- The September 2026 expert hearing
- MDL 3163: the vision-loss court
- Stomach paralysis (gastroparesis) claims
- NAION vision-loss claims
- The gastric emptying study, explained
- How compensation works
- Is it too late to file?
- For spouses & caregivers